NCT03785210View on ClinicalTrials.gov

Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic Cancers

PHASE2CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

June 5, 2019

Primary Completion Date

October 31, 2022

Study Completion Date

December 31, 2022

Conditions
Hepatocellular CarcinomaHepatocellular CancerMetastatic Pancreatic CancerMetastatic Colorectal CancerLiver Metastasis
Interventions
DRUG

nivolumab

480 mg intravenous (IV) every 4 weeks

DRUG

tadalafil

10 mg by mouth (PO) daily

DRUG

oral vancomycin

125 mg every 6-hour (500 mg total daily dose) by mouth (PO) from week 1 to week 3, week 4 off.

Trial Locations (1)

20892

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT03785210 - Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic Cancers | Biotech Hunter | Biotech Hunter